RT234 is a novel investigational therapy combining inhaled dry powder vardenafil with a proprietary oscillating inhaler, designed for rapid, on-demand relief of breathlessness in patients with pulmonary arterial hypertension (PAH). In a phase 2b CPET study, RT234 demonstrated dose-dependent improvements in peak VO₂ and dyspnea. As part of our ATS 2025 coverage, Dr Raymond Benza discusses these findings, current treatment limitations, and the next steps toward a phase III clinical trial.

In this episode, Professor Irene Higginson, Director of Better Health and Care Futures at King’s College London, discusses the complex challenges of managing breathlessness. She explores non-pharmacological strategies, the value of multidisciplinary care, and how the Breathlessness Support Services at KCL are transforming patient support. Tune in for expert insights and a look at future directions in breathlessness research and care.

A new European Respiratory Society (ERS) statement on preschool wheezing disorders represents a significant update in the approach to diagnosing and managing this complex condition in young children.

Approximately half of all smokers will develop chronic obstructive pulmonary disease (COPD), with a disease progression over several years before the spirometric threshold for diagnosis is reached.1 There is, therefore, a clear benefit in identifying patients with COPD as early ...

The nasal airway serves as the primary entry point of air and oxygen into the body. It serves critical functions, such as providing a physical barrier against external irritants and pathogens and warming and humidifying incoming air.1 Consequently, disorders of ...

Interstitial lung diseases (ILDs) are a heterogeneous group of disorders characterized by inflammation and/or fibrosis.1 Pulmonary fibrosis develops due to repeated cycles of injury and impaired repair with fibroblast activation and migration with the resultant deposition of extracellular matrix ...

Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are the dominant cause of the worsening and high mortality of chronic obstructive pulmonary disease (COPD), and are associated with higher healthcare costs as part of COPD management. AECOPD is characterized by ...

The topic of the carbon footprint of human activities is one frequently discussed worldwide. There have been conscious efforts across multiple fields, including healthcare, to reduce their carbon footprint. In Canada, 4.6% of greenhouse gases (GHG) are manufactured by the healthcare ...

The natural progression of neuromuscular disease (NMD) inevitably involves respiratory system failure. Increasing respiratory muscle weakness causes worsening hypoventilation, leading to hypercapnia and, eventually, hypoxemia. The American College of Chest Physicians (CHEST) recently published guidelines on the respiratory management of ...